The Adimab and GV-backed covid-19 antibody treatment developer has floated on Nasdaq at a $1.84bn valuation, about a year after it was founded.

Cigna Ventures returned to back an $83.5m round for the kidney care provider that also featured new investor Blue Shield of California.

University of Oxford’s genetic therapeutics spinout has secured the crossover funding eight months after a series A round also backed by OSI.

The Angelini Lumira Biosciences Fund will invest in early-stage companies in Canada and the US.

JD Health has backed a $93m series D round for Rimag, while a couple of India-based startups delivered exits.

The China Union-backed drug contract manufacturer has raised the funding approximately a year and a half after a $60m series A.

Bayer is set to acquire the precision therapeutics developer backed by Alexandria Venture Investments, Celgene and SoftBank, with another $500m in milestone payments up for grabs.

Osage University Partners has backed the immunotherapy developer in a series B round, which took its overall funding to over $335m.

Alphabet, Eli Lilly, Dong-A ST and Alexandria Real Estate Equities backed the immunotherapy developer in a series B round, which took its overall funding to over $335m.

China Merchants Capital has co-led a series B round sized at almost $99.2m that also attracted existing shareholder Legend Capital.